Roivant Sciences Ltd.
ROIV
$28.58
-$0.95-3.22%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -299.77M | -809.24M | -373.97M | -490.63M | -171.98M |
| Total Depreciation and Amortization | 3.35M | 10.87M | 12.13M | 13.12M | 14.07M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 167.87M | 25.51M | -359.31M | -328.02M | -604.50M |
| Change in Net Operating Assets | -621.80M | 13.77M | -48.71M | -45.48M | -77.05M |
| Cash from Operations | -750.35M | -759.10M | -769.86M | -851.01M | -839.45M |
| Capital Expenditure | -8.21M | -7.76M | -14.52M | -7.67M | -4.60M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -4.42M | 74.93M | 229.36M | 339.75M | 339.75M |
| Other Investing Activities | -669.71M | 151.20M | 348.13M | -3.18B | -2.10B |
| Cash from Investing | -682.33M | 218.37M | 562.97M | -2.85B | -1.77B |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | 0.00 | -49.09M | -50.92M | -52.75M |
| Issuance of Common Stock | 269.51M | 231.29M | 140.21M | 78.41M | 50.63M |
| Repurchase of Common Stock | -366.72M | -551.07M | -779.19M | -887.22M | -1.33B |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 231.46M | 345.64M | 112.78M | 112.78M | 112.78M |
| Cash from Financing | 134.24M | 25.86M | -575.29M | -746.95M | -1.22B |
| Foreign Exchange rate Adjustments | 3.77M | 1.96M | 465.00K | 4.30M | 747.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -1.29B | -512.90M | -781.71M | -4.44B | -3.82B |